Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01618864 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea
A NA study, sponsored by Syneron Medical.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01618864: Completed NA study, sponsored by Syneron Medical.
NCT01618864 is a NA study that has completed, run by Syneron Medical. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01618864, a NA study, has completed, sponsored by Syneron Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of the Luxe™ device for use in wrinkle and rosacea treatment. Up to 60 subjects will treat their periorbital and cheek areas daily for 4 weeks and then twice a week for an additional 4 weeks. Evaluations of improvement will be conducted at the clinic after enrollment and during the treatment at 1, 2, 4, and 8 weeks after initiation.
Primary Outcome
Data reported as percentage of participants showing improvement in overall score as assessed by investigator. 5 point scale of 0 (no difference) to 4 (Significantly marked improvement)provided for overall improvement in skin texture, roughness, skin color (even/blotchy), erythema and photo-damage.
Interventions
- DEVICE Luxe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-12 |
| Phase | NA |
What the finished NCT01618864 record still lists
NCT01618864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Luxe is the first listed.
NCT01618864 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01618864 about?
NCT01618864 is a clinical study titled "Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea". This study is designed to evaluate the efficacy and safety of the Luxe™ device for use in wrinkle and rosacea treatment. Up to 60 subjects will treat their periorbital and cheek areas daily for 4 weeks and then twice a week for an additional 4 weeks. Evaluations of improvement will be conducted at ...
What is the current status of trial NCT01618864?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2012-03. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01618864?
The interventions under investigation include: Luxe (DEVICE).
Who is sponsoring clinical trial NCT01618864?
This trial is sponsored by Syneron Medical, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01618864's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia